| abstract |
The present invention relates to novel antisense (AS) oligos containing one or more antisense sequence to mRNA region with a less secondary structure. Particularly, the present invention relates to a covalently-closed multiple antisense (CMAS)-oligo, which is constructed to form a closed type by ligation using complementary primer, and a ribbon-type antisense (RiAS)-oligo, which is composed of two loops containing multiple antisense sequences and a stem connecting the two loops that is constructed to by ligation using complementary sequences at both 5 prime ends. Since the novel AS-oligos of this invention are extremely stable to exonuclease activities, and show a significant growth inhibition of tumor cells, pharmaceutical compositions containing the novel types of AS-oligos of the invention are effective for treatment cancer, immune diseases, infectious diseases, and other human diseases caused by aberrant gene expression. |